Trial Profile
Phase 2 study of SAB-301 in patients with Middle-East-respiratory-syndrome-coronavirus
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2016
Price :
$35
*
At a glance
- Drugs MERS monoclonal antibody (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Therapeutic Use
- 14 Sep 2016 New trial record
- 24 Aug 2016 According to SAB Biotherapeutics media release, this trial is conducted by the National Institutes of Health (NIH).